Form 4: Gain Therapeutics CEO Matthias Alder Reports Stock Transactions
SEC Form 4 Filing
CEO Matthias Alder reports transactions involving restricted stock units and common stock of Gain Therapeutics.
Summary
- Matthias Alder, CEO of Gain Therapeutics, reported transactions involving the company's stock on March 26, 2024.
- These transactions included the vesting of restricted stock units (RSUs) and the subsequent acquisition of common stock.
- Alder acquired 18,750, 825, and 637 shares of common stock upon the vesting of RSUs.
- The company withheld 6,085 shares to satisfy tax withholding requirements at a price of $4.06 per share.
- Following these transactions, Alder directly owns 21,140 shares of common stock.
- Alder also directly owns 56,250, 8,250, and 6,376 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 03/26/2024 | Date of stock transactions (vesting of RSUs and acquisition/disposal of common stock). |
| 03/28/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.